Previous 10 | Next 10 |
EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889 A...
Gainers: Ebang International (NASDAQ: EBON ) +42% . More news on: Ebang International Holdings Inc., Cardiff Oncology, Inc., Herman Miller, Inc., Stocks on the move, , Read more ...
Strongbridge Biopharma (NASDAQ: SBBP ) -16% after pricing $25M share offering. More news on: Strongbridge Biopharma plc, NuCana plc, Dave & Buster's Entertainment, Inc., Stocks on the move, , Read more ...
NuCana (NASDAQ: NCNA ) -12% has priced its public offering of 15.5M ADS at $4.50 per ADS, for total gross proceeds of ~$70M. More news on: NuCana plc, Healthcare stocks news, Stocks on the move, Read more ...
EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Sha...
NuCana (NASDAQ: NCNA ) has commenced an underwritten public offering of its American Depositary Shares ((ADSs)). Each ADS represents one ordinary share of NuCana. More news on: NuCana plc, Healthcare stocks news, , Read more ...
EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary ...
NuCana (NASDAQ: NCNA ) : Q2 GAAP EPS of -£0.19. More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics. As of June 30, 2020, NuCana had...
EDINBURGH, United Kingdom, May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference. Event: Jeff...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...